1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Smallpox - Pipeline Review, H1 2016

Smallpox - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 86 pages

Smallpox - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Smallpox - Pipeline Review, H1 2016’, provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
- The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Smallpox - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Smallpox Overview 8
Therapeutics Development 9
Pipeline Products for Smallpox - Overview 9
Pipeline Products for Smallpox - Comparative Analysis 10
Smallpox - Therapeutics under Development by Companies 11
Smallpox - Therapeutics under Investigation by Universities/Institutes 12
Smallpox - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Smallpox - Products under Development by Companies 15
Smallpox - Products under Investigation by Universities/Institutes 16
Smallpox - Companies Involved in Therapeutics Development 17
Bavarian Nordic A/S 17
CEL-SCI Corporation 18
Chimerix, Inc. 19
EpiVax, Inc. 20
Nanotherapeutics, Inc. 21
SIGA Technologies, Inc. 22
Symphogen A/S 23
Takeda Pharmaceutical Company Limited 24
TapImmune Inc. 25
Tonix Pharmaceuticals Holding Corp. 26
Smallpox - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(plague + small pox) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
24a - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
brincidofovir - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
CEL-1000 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
cidofovir - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
imatinib mesylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Monoclonal Antibodies for Infectious Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
nilotinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
PL-801 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
SCV-305 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
small pox vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
smallpox vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
smallpox vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Sym-002 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
tecovirimat - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
TPIV-300 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
VIR-002 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Smallpox - Recent Pipeline Updates 61
Smallpox - Dormant Projects 77
Smallpox - Discontinued Products 78
Smallpox - Product Development Milestones 79
Featured News and Press Releases 79
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 79
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 79
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 80
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 80
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 81
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 81
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 82
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 83
Dec 23, 2014: Chimerix Provides Recap of 2014 Events 83
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables
Number of Products under Development for Smallpox, H1 2016 9
Number of Products under Development for Smallpox - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Smallpox - Pipeline by Bavarian Nordic A/S, H1 2016 17
Smallpox - Pipeline by CEL-SCI Corporation, H1 2016 18
Smallpox - Pipeline by Chimerix, Inc., H1 2016 19
Smallpox - Pipeline by EpiVax, Inc., H1 2016 20
Smallpox - Pipeline by Nanotherapeutics, Inc., H1 2016 21
Smallpox - Pipeline by SIGA Technologies, Inc., H1 2016 22
Smallpox - Pipeline by Symphogen A/S, H1 2016 23
Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24
Smallpox - Pipeline by TapImmune Inc., H1 2016 25
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Assessment by Combination Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Smallpox Therapeutics - Recent Pipeline Updates, H1 2016 61
Smallpox - Dormant Projects, H1 2016 77
Smallpox - Discontinued Products, H1 2016 78

List of Figures
Number of Products under Development for Smallpox, H1 2016 9
Number of Products under Development for Smallpox - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Targets, H1 2016 29
Number of Products by Stage and Targets, H1 2016 29
Number of Products by Mechanism of Actions, H1 2016 31
Number of Products by Stage and Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.